This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Onyx Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Onyx Pharmaceuticals (ONXX)

Q2 2012 Earnings Call

August 01, 2012 5:00 pm ET

Executives

Amy Figueroa

N. Anthony Coles - Chief Executive Officer, President and Director

Helen Torley - Chief Commercial officer and Executive Vice President

Matthew K. Fust - Chief Financial Officer, Principal Accounting Officer and Executive Vice President

Barbara Klencke

Analysts

Michael G. King - Rodman & Renshaw, LLC, Research Division

Cory William Kasimov - JP Morgan Chase & Co, Research Division

Terence C. Flynn - Goldman Sachs Group Inc., Research Division

Rachel L. McMinn - BofA Merrill Lynch, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Biren Amin - Jefferies & Company, Inc., Research Division

Matthew R. Wooten - Robert W. Baird & Co. Incorporated, Research Division

Navdeep Singh - Deutsche Bank AG, Research Division

Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division

Ling Wang - Summer Street Research Partners

Echo Yinghui He - Maxim Group LLC, Research Division

Ryan Martins - Lazard Capital Markets LLC, Research Division

Nicholas Bishop - Cowen and Company, LLC, Research Division

Ying Huang - Barclays Capital, Research Division

Marshall Urist - Morgan Stanley, Research Division

Jim Birchenough - BMO Capital Markets U.S.

Presentation

Operator

Welcome to the Onyx Pharmaceuticals Conference Call. My name is Trish, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded.

I would now like to turn the call over to Onyx Pharmaceuticals.

Amy Figueroa

Thanks, Trish. Good afternoon. I'm Amy Figueroa, Senior Director of Investor Relations at Onyx Pharmaceuticals. Thank you for participating on our second quarter 2012 financial results conference call.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs